Lista de obras -

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options

artículo científico publicado en 2019

An overview of antibody-drug conjugates in oncological practice

artículo científico publicado en 2020

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

artículo científico publicado en 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib for treating myeloma

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature

artículo científico publicado en 2020

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Combination of conventional culture, vial culture, and broad-range PCR of sonication fluid for the diagnosis of prosthetic joint infection

scientific article published on 21 April 2018

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

artículo científico publicado en 2019

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

artículo científico publicado en 2018

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

artículo científico publicado en 2018

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

artículo científico publicado en 2016

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

artículo científico publicado en 2018

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

artículo científico publicado en 2016

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma

artículo científico publicado en 2020

Immunotherapy for pancreatic cancer: A 2020 update

scientific article published on 25 March 2020

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

scientific article published on 01 October 2019

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

artículo científico publicado en 2019

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma

scientific article published on 09 April 2020

Prognostic factors for multiple myeloma in the era of novel therapies

artículo científico publicado en 2018

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome

artículo científico publicado en 2019

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

scientific article published on 04 September 2019

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

artículo científico publicado en 2017

Treating ALK-positive non-small cell lung cancer.

artículo científico publicado en 2018

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients

scientific article published on 10 January 2019

Lista de obras de

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options

An overview of antibody-drug conjugates in oncological practice

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Carfilzomib for treating myeloma

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Combination of conventional culture, vial culture, and broad-range PCR of sonication fluid for the diagnosis of prosthetic joint infection

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma

Immunotherapy for pancreatic cancer: A 2020 update

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma

Prognostic factors for multiple myeloma in the era of novel therapies

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

Treating ALK-positive non-small cell lung cancer.

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients